PMS Registry
Company Name
Astellas Pharma Taiwan, Inc.
Protocol Number
Title of Study
A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)
Primary Objective
To establish the safety profile of ELIGARD® in ethnic Asian prostate cancer patients
Number of Sites
Approximately 20 centers in 8 Asian Countries (Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam); 3 site in Taiwan
Period of Study
From:June 2017 to:April 2020
Number of Patients
IRB Approval Date
TCVGH: 16May2017
CMUH: 20Oct2016
TSGH: 19May2017
Publication Plan / Date